The Overlap Between PMDD and ADHD: What the Research Shows
Premenstrual dysphoric disorder (PMDD) and attention-deficit/hyperactivity disorder (ADHD) are typically discussed as separate conditions—one classified as a mood disorder tied to the menstrual cycle, the other as a neurodevelopmental disorder affecting attention and impulse control. Emerging research indicates that the two frequently co-occur, and that the biological mechanisms behind ADHD may make some individuals more vulnerable to PMDD.
What Each Condition Involves
PMDD is a severe form of premenstrual syndrome marked by significant mood disturbance—irritability, depression, anxiety, or emotional lability—that emerges in the luteal phase (the one to two weeks before menstruation) and resolves shortly after bleeding begins. It affects an estimated 3–8% of menstruating individuals and is recognized as a distinct diagnosis in the DSM-5.
ADHD is a neurodevelopmental condition involving persistent patterns of inattention, hyperactivity, and/or impulsivity that begin in childhood and often continue into adulthood. Historically, ADHD has been underdiagnosed in girls and women, in part because presentations are more often inattentive than hyperactive and are frequently misattributed to anxiety or mood issues.
Evidence of Co-Occurrence
A 2025 cross-sectional survey study published in the British Journal of Psychiatry examined 715 participants assigned female at birth, aged 18–34. Researchers compared rates of provisional PMDD (assessed via the Premenstrual Symptoms Screening Tool) among those with self-reported clinical ADHD diagnoses, those meeting a symptom-based ADHD threshold, and a non-ADHD reference group. Provisional PMDD prevalence was 31.4% among those with a clinical ADHD diagnosis and 41.1% among those meeting the symptom-based threshold, compared with 9.8% in the reference group. Risk was highest among those with ADHD alongside a depression or anxiety diagnosis, at more than four times the risk of the reference group (relative risk 4.53) (Broughton et al., 2025, Br J Psychiatry).
The study's authors note that clinicians should be aware that individuals with ADHD, or with elevated ADHD symptom levels, may be more likely to experience PMDD, and that the underlying mechanisms connecting the two conditions remain an open area of research.
Why the Two May Be Linked
A 2025 narrative review in the Journal of Clinical Medicine examined 29 studies on menstrual cycle-related hormonal fluctuations and ADHD. It found that while attentional processing appeared enhanced during the mid-luteal phase in non-clinical populations—possibly linked to rising progesterone—women with ADHD, and those with PMS or PMDD, consistently showed impairments in attention, executive function, and impulse control during the mid-luteal and premenstrual phases. Subjective reports of worsened mood, cognition, and reduced ADHD medication efficacy during the luteal phase paralleled these objective findings. The authors propose that these patterns may reflect heightened sensitivity to allopregnanolone (a progesterone metabolite) and to the sharp drop in estrogen that precedes menstruation, combined with an absence of the compensatory neural adaptations seen in people without ADHD (Wynchank et al., 2025, J Clin Med).
A related 2026 review in Biological Psychiatry frames PMDD as a "cycle-specific" condition and ADHD as a "cycle-responsive" condition—both showing symptom escalation during the luteal phase, tied to ovarian hormone withdrawal and its downstream effects on serotonin, GABA, dopamine, and norepinephrine systems. The authors argue that PMDD offers a useful model for understanding hormone-linked symptom fluctuation more broadly, including in ADHD (May et al., 2026, Biological Psychiatry).
Clinical and Practical Implications
Because ADHD medications primarily target dopamine and norepinephrine, and estrogen influences dopaminergic signaling, cyclical hormone shifts may partly explain why some individuals report that stimulant medication feels less effective in the days before their period. This has led some clinicians to explore cycle-informed approaches to ADHD care. A 2024 study describing a female-specific ADHD treatment group found that structured cycle tracking—paired with education about hormone-related symptom shifts—improved participants' self-understanding and sense of control over fluctuating symptoms (de Jong et al., 2024, J Clin Med).
For individuals with ADHD who notice a consistent monthly pattern of worsening mood, irritability, or executive dysfunction in the week or two before their period, tracking symptoms across at least two cycles (using a tool such as the Daily Record of Severity of Problems) can help clarify whether PMDD is also present. This information is useful to bring to a clinician, since PMDD and ADHD may each require distinct—though sometimes complementary—treatment approaches, including SSRIs, hormonal interventions, or adjustments to stimulant timing.
A Note on the Evidence
Research in this area remains limited. Study samples are often small, cross-sectional designs cannot establish causation, and the field has historically underinvested in research on ADHD in women. The authors of the studies cited above consistently call for further work to clarify the biological mechanisms linking these conditions and to develop female-specific diagnostic and treatment protocols.
This article is for informational purposes and is not a substitute for individualized medical advice. Readers experiencing symptoms of PMDD, ADHD, or both should consult a qualified healthcare provider.
Sources
Broughton, T., Lambert, E., Wertz, J., & Agnew-Blais, J. (2025). Increased risk of provisional premenstrual dysphoric disorder (PMDD) among females with attention-deficit hyperactivity disorder (ADHD): cross-sectional survey study. British Journal of Psychiatry, 226(6), 410–417. https://doi.org/10.1192/bjp.2025.104 Wynchank, D., Sutrisno, R. M. G. T. M. F., van Andel, E., & Kooij, J. J. S. (2025). Menstrual Cycle-Related Hormonal Fluctuations in ADHD: Effect on Cognitive Functioning—A Narrative Review. Journal of Clinical Medicine, 15(1). https://doi.org/10.3390/jcm15010121 May, E., et al. (2026). Timing Matters: Leveraging Positron Emission Tomography Imaging and Hormonal Cycles for Precision Psychiatry in Female Mental Health. Biological Psychiatry. de Jong, M., et al. (2024). A Female-Specific Treatment Group for ADHD—Description of the Programme and Qualitative Analysis of First Experiences. Journal of Clinical Medicine.
